CL2022003187A1 - Compuestos de insulina acilada de acción temporal prolongada - Google Patents

Compuestos de insulina acilada de acción temporal prolongada

Info

Publication number
CL2022003187A1
CL2022003187A1 CL2022003187A CL2022003187A CL2022003187A1 CL 2022003187 A1 CL2022003187 A1 CL 2022003187A1 CL 2022003187 A CL2022003187 A CL 2022003187A CL 2022003187 A CL2022003187 A CL 2022003187A CL 2022003187 A1 CL2022003187 A1 CL 2022003187A1
Authority
CL
Chile
Prior art keywords
compounds
acylated insulin
long
insulin compounds
acting
Prior art date
Application number
CL2022003187A
Other languages
English (en)
Inventor
Francisco Alcides VALENZUELA
Wen Liu
Seamus Patrick Brennan
David Benjamin Flora
Valdislav Kisselev
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CL2022003187A1 publication Critical patent/CL2022003187A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

Los compuestos descritos en la presente se refieren al tratamiento de la diabetes tipo I y/o tipo II y/o la hiperglucemia. Más particularmente, los compuestos descritos se refieren a compuestos de insulina acilada de acción temporal prolongada que reducen la glucosa en sangre, composiciones farmacéuticas que contienen tales compuestos, usos terapéuticos de tales compuestos y un compuesto intermediario usado para fabricar los compuestos de insulina acilada.
CL2022003187A 2020-05-15 2022-11-15 Compuestos de insulina acilada de acción temporal prolongada CL2022003187A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063025463P 2020-05-15 2020-05-15

Publications (1)

Publication Number Publication Date
CL2022003187A1 true CL2022003187A1 (es) 2023-03-03

Family

ID=78524979

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003187A CL2022003187A1 (es) 2020-05-15 2022-11-15 Compuestos de insulina acilada de acción temporal prolongada

Country Status (16)

Country Link
US (1) US20230174609A1 (es)
EP (1) EP4149516A1 (es)
JP (1) JP7456007B2 (es)
KR (1) KR20230009499A (es)
CN (1) CN115867308A (es)
AU (1) AU2021273262A1 (es)
BR (1) BR112022022885A2 (es)
CA (1) CA3177905A1 (es)
CL (1) CL2022003187A1 (es)
CO (1) CO2022016338A2 (es)
CR (1) CR20220641A (es)
EC (1) ECSP22087958A (es)
IL (1) IL297976A (es)
MX (1) MX2022014309A (es)
PE (1) PE20230832A1 (es)
WO (1) WO2021231676A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN115947822B (zh) * 2022-07-04 2023-08-18 北京惠之衡生物科技有限公司 一种长效酰化胰岛素衍生物及其药物组合物和应用
CN115894719B (zh) * 2022-11-24 2023-10-20 武汉禾元生物科技股份有限公司 一种人血清白蛋白胰岛素偶联物及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5693609A (en) * 1994-11-17 1997-12-02 Eli Lilly And Company Acylated insulin analogs
US6444641B1 (en) * 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
TR200001050T2 (tr) * 1997-10-24 2000-08-21 Eli Lilly And Company Çözünmez insülin bileşimleri
EP2170945A1 (en) * 2007-07-16 2010-04-07 Novo Nordisk A/S Protease stabilized, pegylated insulin analogues
TW201716432A (zh) * 2015-07-06 2017-05-16 諾佛 儂迪克股份有限公司 新穎肽與肽衍生物及其用途
JOP20190273A1 (ar) * 2017-05-26 2019-11-24 Lilly Co Eli مركب إنسولين معالج بأسيل

Also Published As

Publication number Publication date
KR20230009499A (ko) 2023-01-17
US20230174609A1 (en) 2023-06-08
JP2023526069A (ja) 2023-06-20
WO2021231676A1 (en) 2021-11-18
PE20230832A1 (es) 2023-05-19
ECSP22087958A (es) 2022-12-30
CN115867308A (zh) 2023-03-28
IL297976A (en) 2023-01-01
CO2022016338A2 (es) 2022-11-29
CA3177905A1 (en) 2021-11-18
JP7456007B2 (ja) 2024-03-26
EP4149516A1 (en) 2023-03-22
BR112022022885A2 (pt) 2022-12-20
AU2021273262A1 (en) 2022-12-08
MX2022014309A (es) 2022-12-07
CR20220641A (es) 2023-01-19

Similar Documents

Publication Publication Date Title
CL2022003187A1 (es) Compuestos de insulina acilada de acción temporal prolongada
ECSP19083930A (es) Compuesto de insulina acilada
CL2023000086A1 (es) Análogos de insulina novedosos y usos de estos(div 202201400)
CO6400181A2 (es) Compuestos de tiazolopiridina moduladores de sirtuina
AR039063A1 (es) Derivados de diarilcicloalquilo, procedimiento para su preparacion, medicamento, un proceso para su preparacion, utilizacion de dichos derivados para la preparacion de un medicamento
AR099569A1 (es) Derivados de insulina y los usos médicos de estos
AR116605A1 (es) Compuestos bifuncionales que comprenden péptidos de insulina y péptidos de egf(a)
CO2019006017A2 (es) Composiciones farmacéuticas que contienen insulina
AR106364A1 (es) Derivados de insulina y sus usos médicos
UY38986A (es) Compuestos derivados de 3-(5-metoxi-1-oxoisoindolin-2-il) piperidin-2,6-diona, métodos de usos de los mismos y combinaciones farmacéuticas
CO6640324A2 (es) Uso de metformina en combinación con un activador de glucoquinasa y composiciones que comprenden metformina y un activador de glucoquinasa
CR20170209A (es) Análogos de urea unidos sustituidos como moduladores de sirtuina
CO2022015930A2 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
AR120057A1 (es) Composiciones neoantigénicas y usos de estas
CL2022003041A1 (es) Compuestos heterocíclicos como agonistas del receptor de activación expresado en las células mieloides 2
BRPI0916507A8 (pt) Compostos, composição cosmética, processo de tratamento cosmético não terapêutico da pele e usos não terapêuticos de uma composição cosmética
BR112012007991A2 (pt) inibidores de cxcr1/2 como adjuvantes no transplante de ilhotas pancreáticas
ECSP24000004A (es) Derivados de 3–(1–oxoisoindolin–2–il)piperidina–2,6–diona y sus usos médicos
BR112022003633A2 (pt) Métodos para produção de arginase 1 recombinante humana e usos da mesma
ECSP22093652A (es) Compuestos de imidazopiridazina y usos de los mismos
AR038046A1 (es) Derivados de acidos 3-fenil-2-arilalquiltiopropionicos moduladores de ppar alfa
ECSP23076800A (es) Derivados de pirazolopiridina y sus usos
BR102018010523A2 (pt) peptídeo, composição farmacêutica compreendendo o mesmo e uso
AR030620A1 (es) Compuestos derivados de acido bencenotricarboxilico, un proceso para su preparacion, composicion farmaceutica que los comprenden, metodo para efectuar ensayo y el uso de los mismos para la manufactura de medicamentos como activadores del receptor de insulina y para la preparacion de agentes de diagn
AR057594A1 (es) Acido 2,3,4,5-tetrahidroxi-6-sulfooxi hexanoico, sales de este aceptables para el uso farmaceutico y sus formas de equilibrio, proceso para su preparacion, composiciones farmaceuticas que comprenden estos compuestos y su uso medico